Developer docs
API playgroundTry for free, no card

Search company profiles

RegenLab USA

Full company profile

uuid0007wq4

Namestring
RegenLab USA
Legal namestring
Regenlab USA LLC
Websiteurl
regenlabusa.com
Company typeenum
Private
Founded yearint
2003
Descriptiontext

RegenLab USA LLC is the U.S. operating subsidiary of Swiss-founded Regen Lab SA (est. 2003) and manufactures/distributes medical devices for autologous platelet-rich plasma (PRP) preparation under FDA 510(k) clearance, with operational headquarters in Jersey City, NJ. The company's core product line comprises single-use evacuated borosilicate tube kits (RegenKit BCT, THT, Wound Gel, Enhanced HA) and the Regen ATS autologous thrombin serum device, all built on a proprietary thixotropic gel separation technology protected by granted U.S., European, and Swiss patents. Centrifugation at 1500 g causes the thixotropic gel to form a stable physical barrier isolating platelets and plasma from erythrocytes and granulocytes, yielding standardized PRP with >80% platelet recovery and >99.7% RBC elimination. The technology supports multiple cellular selectivity profiles (RegenPlasma leukocyte-poor vs. RegenCell mononuclear-selective) and concentration flexibility (1.6x to 6.9x baseline).

Revenue is generated primarily through one-time sales of single-use medical device kits to healthcare professionals across three primary segments: wound care specialists (CMS-reimbursed under HCPCS G0465 via MiMedx Group exclusive U.S. distribution); orthopedic surgeons and sports medicine physicians (RegenKit-THT/BCT for knee OA, tendinopathy, bone graft augmentation); and dermatologists/aesthetic practitioners (Enhanced HA for hair loss and skin rejuvenation). Pricing is not publicly disclosed; orders are placed through Account Support (info@regenlabusa.com) and online account portals, with enterprise-level Doctor-to-Doctor Sales Advisors targeting hospitals and wound care centers. Sales reps carry monthly targets of $100K with commission of 5% on new clients and 4% on recurring/dormant accounts. An additional revenue stream comes through proprietary technology licensing via Regen Lab SA's global patent portfolio. Across the parent group, Regen Lab operates ~145 employees (30 US, 75 Switzerland HQ, 40 France), sells in 160+ countries, and has treated over 2 million patients with RegenLab technology.

Short descriptiontext

RegenLab USA LLC manufactures and distributes FDA-cleared medical device kits for autologous platelet-rich plasma (PRP) preparation, serving wound care specialists, orthopedic surgeons, and dermatologists in the United States via proprietary thixotropic gel separation technology.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersJersey City, United States
HQ citystring
Jersey City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
platelet-rich plasma devices, regenerative medicine kits, autologous PRP systems, wound care devices, orthopedic medical devices
Industry3 codes
PRIMARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAIAHAG
Fibrin Sealants & Plasma-Derived Surgical Hemostats (Fibrinogen/Thrombin)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code3 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
  • Wholesale-Medical, Dental & Hospital Equipment & Supplies5047
Product category
Regenerative Medicine Medical Devices
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model3 records
1RegenKit® Medical Device Sales
TypeOne Time License
Description

RegenLab USA sells single-use medical device kits (RegenKit® BCT, THT, Wound Gel, Enhanced HA, ATS) and supplemental devices (centrifuges, applicators, blood draw accessories) to healthcare professionals. Products are sold directly via sales team and through the MiMedx distribution partnership for Wound Gel. Revenue is generated per kit/unit sold.

regenlabusa.com
2Proprietary Technology Licensing
TypeLicensing Royalties
Description

RegenLab licenses its patented thixotropic gel technology and A-PRP® preparation methods globally through sister company Regen Lab SA. The company holds an extensive portfolio of U.S., European, and Swiss patents covering PRP preparation, BMC gel devices, ATS, PRP+HA combinations (Cellular Matrix®), and associated technologies.

regenlabusa.com
3Supplemental Devices and Accessories
TypeHardware Sales
Description

Sale of complementary devices including the Horizon 6FA Centrifuge, Regen® Spray Applicator, Neo Oxus Trocar, and blood draw accessory sets (Safety-Lok™ Butterfly needles, collection holders, transfer devices, syringes) compatible with RegenKit® products.

regenlabusa.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 10 records shown
1RegenPRP™
Description

Medical treatment using platelet-rich plasma from the patient's own blood to enhance tissue regeneration.

regenlabusa.com
+9 more records
Core offering1 text field

RegenLab USA LLC manufactures and distributes single-use medical device kits and laboratory products that enable healthcare professionals to prepare autologous platelet-rich plasma (PRP) at the point of care. Its portfolio includes the RegenKit family (BCT, THT, Wound Gel), Regen ATS for autologous thrombin serum, Enhanced HA combining PRP with hyaluronic acid, and supplemental devices (centrifuge, spray applicator, blood draw accessories) used in wound care, orthopedics, dermatology, and aesthetic applications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Platelet recovery >80% (BCT) and >95% (THT); RBC elimination >99.7% (BCT) and >99% (THT); Granulocyte removal ~96.5% (BCT) and 85-90% (THT)
+4 more records
Product overview1 text field

RegenLab USA LLC offers a comprehensive portfolio of medical devices for autologous regenerative medicine, centered on their proprietary thixotropic gel technology for platelet-rich plasma (PRP) preparation. The core product line includes RegenPRP™ treatment combined with RegenKit® medical device kits (BCT, THT®, Wound Gel) and Regen® ATS for coagulation activation. Additional offerings include Enhanced HA combining PRP with hyaluronic acid, and supplemental devices such as the Horizon 6FA Centrifuge, Spray Applicator, and Blood Draw Accessories. The portfolio provides concentration flexibility through different cellular selectivity models (RegenPlasma® leukocyte-poor and RegenCell® monocyte-selective), enabling individualized therapeutic approaches for wound care, orthopedics, dermatology, and aesthetic applications. Distribution is handled through exclusive partnerships including MiMedx for the FDA-approved RegenKit-Wound Gel.

Product and service9 records
1RegenKit BCT
CategoryMedical Device Kit
Description

Single-use medical device kit for preparing leukocyte-poor autologous platelet-rich plasma (PRP) at point of care. Achieves >80% platelet recovery and >99.7% RBC elimination. Available in 10 mL and 20 mL configurations for orthopedic, wound care, dermatology, and aesthetic applications.

2RegenKit THT
CategoryMedical Device Kit
Description

Single-use medical device kit for preparing monocyte-selective autologous PRP, designed for mixing with autograft/allograft bone in orthopedic surgical applications. Achieves >95% platelet recovery and 70-80% mononuclear cell recovery. Available in 10 mL and 20 mL configurations.

3RegenKit Wound Gel
CategoryWound Care Medical Device Kit
Description

Single-use medical device kit for preparing autologous PRP wound gel at point of care. Produces ~6.5 mL (Wound Gel-1) or ~13 mL (Wound Gel-2) of gel from patient blood. Achieves 99.7% RBC elimination and >80% platelet recovery. Indicated for chronic diabetic ulcers, pressure ulcers, leg ulcers, and debrided wounds.

4Regen ATS (Autologous Thrombin Serum)
CategoryMedical Device Kit
Description

Single-use medical device kit for preparing autologous thrombin serum that activates PRP coagulation via the physiological coagulation cascade. Produces a 3D fibrin matrix enabling sustained growth factor delivery for tissue repair applications.

5Enhanced HA
CategoryMedical Device Kit
Description

Single-use medical device kit combining platelet-rich plasma with hyaluronic acid in a single tube for skin and joint rejuvenation. Yields ~4 mL of PRP/HA 1:1 mixture per tube with >70% platelet recovery and high purity standards.

6Horizon 6FA Centrifuge
CategorySupplemental Device
Description

Fixed-angle centrifuge designed to complement RegenKit medical devices. Accommodates tubes up to 125 mm including 8 mL, 10 mL, and 20 mL variations with pre-programmed settings for consistent PRP preparation.

7Regen Spray Applicator
CategorySupplemental Device
Description

Class 2 medical device for efficient application of non-homogeneous fluid mixtures such as PRP directly to treatment sites. Designed for evenly dispersing mixtures across larger surface areas for wound healing applications.

8Regen Blood Draw Accessories
CategorySupplemental Device
Description

Blood draw accessory set including Safety-Lok Butterfly needles, collection holders, transfer devices, and syringes designed for efficient and reliable blood collection when used with RegenKit medical devices.

9Neo Oxus Trocar
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-12-22
Description

MiMedx Group, Inc. signed an exclusive U.S. distribution agreement with Regen Lab USA LLC to market RegenKit-Wound Gel, an FDA-approved autologous platelet-rich plasma wound gel cleared in 2022 for treating diabetic chronic wounds. The product is nationally covered by CMS and LCD under HCPCS code G0465 and will complement MiMedx's existing Advanced Wound Care portfolio. The agreement, combined with the upcoming Local Coverage Determination implementation on January 1, 2026, strengthens MiMedx's competitive position heading into the new year. MiMedx also reported strong Q3 2025 earnings (EPS $0.15 vs. $0.06 forecast, revenue $113.7M vs. $94.73M expected), indicating financial strength as a distribution partner.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Arthrex is a leading orthopedic medical device company that offers autologous conditioned plasma (ACP) and other PRP systems for orthopedic and sports medicine applications, directly competing with RegenKit BCT and THT in the same physician-channel market.

TypeDirect peer
Description

EmCyte is a direct competitor in PRP and platelet-rich fibrin preparation kits for orthopedic and aesthetic use, with overlapping product lines (Concentrating Systems, kits) and similar point-of-care preparation approach to RegenLab.

TypeBroad incumbent
Description

Terumo BCT (a Terumo group company) is a global leader in blood component separation technology, offering centrifugal apheresis and PRP collection systems that compete at the higher-volume hospital and blood bank end of RegenLab's market.

TypeBroad incumbent
Description

Zimmer Biomet is a global orthopedic device incumbent that has invested in PRP/orthobiologics (e.g., BioCUE) and competes in musculoskeletal applications where RegenKit THT is used for bone graft and sports medicine.

TypeDirect peer
Description

MiMedx is RegenLab's exclusive U.S. distribution partner for RegenKit-Wound Gel and also a peer in advanced wound care (placental tissue allografts), competing in the same HCPCS-coded wound care segment while serving as channel partner.

TypeDirect peer
Description

Royal Biologics offers autologous regenerative medicine products including PRP kits and amniotic fluid products for orthopedics and wound care, directly competing with RegenLab's kit-based portfolio for physician offices.

TypeDirect peer
Description

Celling Biosciences is a regenerative medicine company specializing in autologous cellular therapies and point-of-care preparation devices, overlapping with RegenLab's bone marrow concentrate (BMC) and PRP preparation positioning in orthopedics.

TypeEmerging player
Description

STRATA Skin Sciences operates in dermatology/aesthetic device space and overlaps with RegenLab's dermatology and PRP-for-hair-loss segments, including similar physician-channel customer bases.

9Collagen Solutions
TypeEmerging player
Description

Collagen Solutions develops biologic medical devices and tissue-based products for wound care and orthopedics, partially overlapping with RegenKit-Wound Gel and orthobiologics applications.

TypeBroad incumbent
Description

Stryker is a broad medical device incumbent with orthopedic, wound care, and surgical portfolios that compete at the hospital system level where RegenLab's RegenKit products are deployed via MiMedx and direct sales.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance7 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

RegenLab USA

Regenerative Medicine Medical Devicesregenlabusa.com

RegenLab USA LLC manufactures and distributes FDA-cleared medical device kits for autologous platelet-rich plasma (PRP) preparation, serving wound care specialists, orthopedic surgeons, and dermatologists in the United States via proprietary thixotropic gel separation technology.

What RegenLab USA does

RegenLab USA LLC is the U.S. operating subsidiary of Swiss-founded Regen Lab SA (est. 2003) and manufactures/distributes medical devices for autologous platelet-rich plasma (PRP) preparation under FDA 510(k) clearance, with operational headquarters in Jersey City, NJ. The company's core product line comprises single-use evacuated borosilicate tube kits (RegenKit BCT, THT, Wound Gel, Enhanced HA) and the Regen ATS autologous thrombin serum device, all built on a proprietary thixotropic gel separation technology protected by granted U.S., European, and Swiss patents. Centrifugation at 1500 g causes the thixotropic gel to form a stable physical barrier isolating platelets and plasma from erythrocytes and granulocytes, yielding standardized PRP with >80% platelet recovery and >99.7% RBC elimination. The technology supports multiple cellular selectivity profiles (RegenPlasma leukocyte-poor vs. RegenCell mononuclear-selective) and concentration flexibility (1.6x to 6.9x baseline).

Revenue is generated primarily through one-time sales of single-use medical device kits to healthcare professionals across three primary segments: wound care specialists (CMS-reimbursed under HCPCS G0465 via MiMedx Group exclusive U.S. distribution); orthopedic surgeons and sports medicine physicians (RegenKit-THT/BCT for knee OA, tendinopathy, bone graft augmentation); and dermatologists/aesthetic practitioners (Enhanced HA for hair loss and skin rejuvenation). Pricing is not publicly disclosed; orders are placed through Account Support (info@regenlabusa.com) and online account portals, with enterprise-level Doctor-to-Doctor Sales Advisors targeting hospitals and wound care centers. Sales reps carry monthly targets of $100K with commission of 5% on new clients and 4% on recurring/dormant accounts. An additional revenue stream comes through proprietary technology licensing via Regen Lab SA's global patent portfolio. Across the parent group, Regen Lab operates ~145 employees (30 US, 75 Switzerland HQ, 40 France), sells in 160+ countries, and has treated over 2 million patients with RegenLab technology.

RegenLab USA firmographics

Firmographics
Name
RegenLab USA
Legal name
Regenlab USA LLC
Website
https://regenlabusa.com
Company type
Private
Founded year
2003
Operating status
Operating
Headcount range
51–100 employees
Short description
RegenLab USA LLC manufactures and distributes FDA-cleared medical device kits for autologous platelet-rich plasma (PRP) preparation, serving wound care specialists, orthopedic surgeons, and dermatologists in the United States via proprietary thixotropic gel separation technology.
Ownership category
akta.pro rank

RegenLab USA industry classification

Industry
Product category
Regenerative Medicine Medical Devices
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)
akta.pro industry
PRIMARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAIAHAG
Fibrin Sealants & Plasma-Derived Surgical Hemostats (Fibrinogen/Thrombin)

Keywords

  • Platelet-rich plasma devices
  • Regenerative medicine kits
  • Autologous PRP systems
  • Wound care devices
  • Orthopedic medical devices

Where RegenLab USA is headquartered

Location

Headquarters

HQ city
Jersey City
HQ country
United States
HQ region
North America

Offices3 records

Markets served

RegenLab USA business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. RegenKit® Medical Device Sales: RegenLab USA sells single-use medical device kits (RegenKit® BCT, THT, Wound Gel, Enhanced HA, ATS) and supplemental devices (centrifuges, applicators, blood draw accessories) to healthcare professionals. Products are sold directly via sales team and through the MiMedx distribution partnership for Wound Gel. Revenue is generated per kit/unit sold.
  2. Proprietary Technology Licensing: RegenLab licenses its patented thixotropic gel technology and A-PRP® preparation methods globally through sister company Regen Lab SA. The company holds an extensive portfolio of U.S., European, and Swiss patents covering PRP preparation, BMC gel devices, ATS, PRP+HA combinations (Cellular Matrix®), and associated technologies.
  3. Supplemental Devices and Accessories: Sale of complementary devices including the Horizon 6FA Centrifuge, Regen® Spray Applicator, Neo Oxus Trocar, and blood draw accessory sets (Safety-Lok™ Butterfly needles, collection holders, transfer devices, syringes) compatible with RegenKit® products.

Go-to-market motion4 records

Distribution channels4 records

Marketing channels7 records

RegenLab USA product offering

Product offering

Core offering

RegenLab USA LLC manufactures and distributes single-use medical device kits and laboratory products that enable healthcare professionals to prepare autologous platelet-rich plasma (PRP) at the point of care. Its portfolio includes the RegenKit family (BCT, THT, Wound Gel), Regen ATS for autologous thrombin serum, Enhanced HA combining PRP with hyaluronic acid, and supplemental devices (centrifuge, spray applicator, blood draw accessories) used in wound care, orthopedics, dermatology, and aesthetic applications.

Product overview

RegenLab USA LLC offers a comprehensive portfolio of medical devices for autologous regenerative medicine, centered on their proprietary thixotropic gel technology for platelet-rich plasma (PRP) preparation. The core product line includes RegenPRP™ treatment combined with RegenKit® medical device kits (BCT, THT®, Wound Gel) and Regen® ATS for coagulation activation. Additional offerings include Enhanced HA combining PRP with hyaluronic acid, and supplemental devices such as the Horizon 6FA Centrifuge, Spray Applicator, and Blood Draw Accessories. The portfolio provides concentration flexibility through different cellular selectivity models (RegenPlasma® leukocyte-poor and RegenCell® monocyte-selective), enabling individualized therapeutic approaches for wound care, orthopedics, dermatology, and aesthetic applications. Distribution is handled through exclusive partnerships including MiMedx for the FDA-approved RegenKit-Wound Gel.

Differentiator

Problem solved

Functional benefit

Brands

  • RegenPRP™: Medical treatment using platelet-rich plasma from the patient's own blood to enhance tissue regeneration.
  • RegenKit® BCT
  • RegenKit® Wound Gel
  • RegenKit® THT®
  • Regen® ATS
  • Enhanced HA
  • A-PRP® Cellular Selectivity
  • RegenWound® Gel
  • Cellular Matrix™
  • BioBridge®

Products and services

  • RegenKit BCT Single-use medical device kit for preparing leukocyte-poor autologous platelet-rich plasma (PRP) at point of care. Achieves >80% platelet recovery and >99.7% RBC elimination. Available in 10 mL and 20 mL configurations for orthopedic, wound care, dermatology, and aesthetic applications.
  • RegenKit THT Single-use medical device kit for preparing monocyte-selective autologous PRP, designed for mixing with autograft/allograft bone in orthopedic surgical applications. Achieves >95% platelet recovery and 70-80% mononuclear cell recovery. Available in 10 mL and 20 mL configurations.
  • RegenKit Wound Gel Single-use medical device kit for preparing autologous PRP wound gel at point of care. Produces ~6.5 mL (Wound Gel-1) or ~13 mL (Wound Gel-2) of gel from patient blood. Achieves 99.7% RBC elimination and >80% platelet recovery. Indicated for chronic diabetic ulcers, pressure ulcers, leg ulcers, and debrided wounds.
  • Regen ATS (Autologous Thrombin Serum) Single-use medical device kit for preparing autologous thrombin serum that activates PRP coagulation via the physiological coagulation cascade. Produces a 3D fibrin matrix enabling sustained growth factor delivery for tissue repair applications.
  • Enhanced HA Single-use medical device kit combining platelet-rich plasma with hyaluronic acid in a single tube for skin and joint rejuvenation. Yields ~4 mL of PRP/HA 1:1 mixture per tube with >70% platelet recovery and high purity standards.
  • Horizon 6FA Centrifuge Fixed-angle centrifuge designed to complement RegenKit medical devices. Accommodates tubes up to 125 mm including 8 mL, 10 mL, and 20 mL variations with pre-programmed settings for consistent PRP preparation.
  • Regen Spray Applicator Class 2 medical device for efficient application of non-homogeneous fluid mixtures such as PRP directly to treatment sites. Designed for evenly dispersing mixtures across larger surface areas for wound healing applications.
  • Regen Blood Draw Accessories Blood draw accessory set including Safety-Lok Butterfly needles, collection holders, transfer devices, and syringes designed for efficient and reliable blood collection when used with RegenKit medical devices.
  • Neo Oxus Trocar

Quantifiable outcome

  • Platelet recovery >80% (BCT) and >95% (THT); RBC elimination >99.7% (BCT) and >99% (THT); Granulocyte removal ~96.5% (BCT) and 85-90% (THT)
  • +4 more outcomes

Companies that use RegenLab USA

Customer profile

Named customers3 records

Segments5 records

Ideal customer profiles4 records

RegenLab USA technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature9 records

RegenLab USA partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • MiMedx Group, Inc.coreChannel Partner/ Reseller/ Distributor · 22 December 2025MiMedx Group, Inc. signed an exclusive U.S. distribution agreement with Regen Lab USA LLC to market RegenKit-Wound Gel, an FDA-approved autologous platelet-rich plasma wound gel cleared in 2022 for treating diabetic chronic wounds. The product is nationally covered by CMS and LCD under HCPCS code G0465 and will complement MiMedx's existing Advanced Wound Care portfolio. The agreement, combined with the upcoming Local Coverage Determination implementation on January 1, 2026, strengthens MiMedx's competitive position heading into the new year. MiMedx also reported strong Q3 2025 earnings (EPS $0.15 vs. $0.06 forecast, revenue $113.7M vs. $94.73M expected), indicating financial strength as a distribution partner.

Scale indicators7 records

Recent moves9 records

Expansion highlights6 records

RegenLab USA competitors and assessment

Company assessment

Broad incumbents

  • Arthrex: Arthrex is a leading orthopedic medical device company that offers autologous conditioned plasma (ACP) and other PRP systems for orthopedic and sports medicine applications, directly competing with RegenKit BCT and THT in the same physician-channel market.
  • Terumo BCT: Terumo BCT (a Terumo group company) is a global leader in blood component separation technology, offering centrifugal apheresis and PRP collection systems that compete at the higher-volume hospital and blood bank end of RegenLab's market.
  • Zimmer Biomet: Zimmer Biomet is a global orthopedic device incumbent that has invested in PRP/orthobiologics (e.g., BioCUE) and competes in musculoskeletal applications where RegenKit THT is used for bone graft and sports medicine.
  • Stryker: Stryker is a broad medical device incumbent with orthopedic, wound care, and surgical portfolios that compete at the hospital system level where RegenLab's RegenKit products are deployed via MiMedx and direct sales.

Direct peers

  • EmCyte Corporation: EmCyte is a direct competitor in PRP and platelet-rich fibrin preparation kits for orthopedic and aesthetic use, with overlapping product lines (Concentrating Systems, kits) and similar point-of-care preparation approach to RegenLab.
  • MiMedx Group: MiMedx is RegenLab's exclusive U.S. distribution partner for RegenKit-Wound Gel and also a peer in advanced wound care (placental tissue allografts), competing in the same HCPCS-coded wound care segment while serving as channel partner.
  • Royal Biologics: Royal Biologics offers autologous regenerative medicine products including PRP kits and amniotic fluid products for orthopedics and wound care, directly competing with RegenLab's kit-based portfolio for physician offices.
  • Celling Biosciences: Celling Biosciences is a regenerative medicine company specializing in autologous cellular therapies and point-of-care preparation devices, overlapping with RegenLab's bone marrow concentrate (BMC) and PRP preparation positioning in orthopedics.

Emerging players

  • STRATA Skin Sciences: STRATA Skin Sciences operates in dermatology/aesthetic device space and overlaps with RegenLab's dermatology and PRP-for-hair-loss segments, including similar physician-channel customer bases.
  • Collagen Solutions: Collagen Solutions develops biologic medical devices and tissue-based products for wound care and orthopedics, partially overlapping with RegenKit-Wound Gel and orthobiologics applications.

Market position

Strengths5 records

Weaknesses3 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

RegenLab USA social profiles

Digital presence

RegenLab USA compliance and trust

Trust signal

Compliance7 records

RegenLab USA financial estimates

Financial estimate

Revenue estimate

Valuation estimate

RegenLab USA leadership team

Management profile

Number of profiles

Profiles2 records

RegenLab USA subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

RegenLab USA funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

RegenLab USA M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RegenLab USA

What does RegenLab USA do?

RegenLab USA LLC manufactures and distributes single-use medical device kits and laboratory products that enable healthcare professionals to prepare autologous platelet-rich plasma (PRP) at the point of care. Its portfolio includes the RegenKit family (BCT, THT, Wound Gel), Regen ATS for autologous thrombin serum, Enhanced HA combining PRP with hyaluronic acid, and supplemental devices (centrifuge, spray applicator, blood draw accessories) used in wound care, orthopedics, dermatology, and aesthetic applications.

Is RegenLab USA a public or private company?

RegenLab USA is a private company. It is classified as corporate owned and is currently operating.

When was RegenLab USA founded?

RegenLab USA was founded in 2003. It employs 51 to 100 people.

Where is RegenLab USA based?

RegenLab USA is headquartered in Jersey City, United States, in the North America region.

How does RegenLab USA make money?

Three revenue lines are on record. RegenKit® Medical Device Sales are the primary driver. The others are proprietary Technology Licensing and supplemental Devices and Accessories.

Who are RegenLab USA's main competitors?

Broad incumbents on record are Arthrex, Terumo BCT, Zimmer Biomet and Stryker. Direct peers are EmCyte Corporation, MiMedx Group, Royal Biologics and Celling Biosciences. Emerging players are STRATA Skin Sciences and Collagen Solutions.

Does RegenLab USA have an API?

No public API is recorded for RegenLab USA.

What industry is RegenLab USA in?

RegenLab USA's product category is Regenerative Medicine Medical Devices. Its primary akta.pro industry code is HLAHALAE, Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts), with a secondary code of HLAAAGAG, Wound Healing & Skin Regeneration (advanced dressings, skin substitutes). Its NAICS code is 325414 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Renaissance CapitalRegenerative medicine device provider RegenLab USA sets terms for $18 million IPORegenLab USA announced IPO terms on Tuesday, planning to raise $18 million by offering 2.5 million shares at $6 to $8. The company, which develops PRP devices, reported $54 million in revenue for the year ended June 30, 2026, and will list on Nasdaq under RGNA.Renaissance CapitalRegenerative medicine device provider RegenLab USA files for a $35 million IPORegenLab USA filed with the SEC to raise up to $35 million in an initial public offering, listing on Nasdaq under RGNA. The company reported $54 million in revenue for the 12 months ended June 30, 2026, and plans to list on Nasdaq.GlobeNewswireMIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit®-Wound GelMiMedx Group, Inc. announced it has entered into an exclusive distribution agreement with Regen Lab USA LLC to distribute RegenKit®-Wound Gel in the United States. The autologous platelet-rich plasma wound gel adds a differentiated option to MIMEDX's Advanced Wound Care portfolio and is covered nationally by CMS and LCD for diabetic chronic wounds under HCPCS code G0465. The company expects the addition to strengthen its competitive position heading into 2026.PR NewswireDe nouveaux brevets américains attribués à RegenLabThe USPTO issued two new US patents to RegenLab SA and RegenLab USA LLC, covering systems and methods for preparing platelet-rich plasma, hyaluronic acid, and thrombin serum using their CELLULAR MATRIX™ technology (patent 10,272,139) and thrombin serum and biological glue systems (patent 10,226,516). This brings the company's total US patents for these technologies to 10, expanding their intellectual property portfolio alongside patents recently granted in other countries. The patents recognize the innovation, technology, and effectiveness of RegenLab's R&D investments in medical devices for PRP-based treatments.PR NewswireNeues US-Patent für RegenLabThe United States Patent and Trademark Office granted two new US patents to Regen Lab SA and RegenLab USA LLC covering technologies for preparing Platelet Rich Plasma and Hyaluronic Acid in medical devices. The new patents (U.S. Patent Nos. 10,272,139 and 10,226,516) bring the company's total US patent count to 10, validating RegenLab's innovation in blood-derived medical technologies. The patents expand RegenLab's intellectual property portfolio alongside recently granted patents in other international jurisdictions.PR NewswireSe conceden nuevas patentes de Estados Unidos a RegenLabRegen Lab SA and RegenLab USA LLC announced that the United States Patent and Trademark Office (USPTO) has issued two new US patents covering their technologies for platelet-rich plasma (PRP), hyaluronic acid (HA), and thrombin serum preparation, including the CELLULAR MATRIX™ all-in-one device technology. The new patents bring the company's total US patent portfolio to 10 patents in these medical technologies. The announcement describes this as recognition of RegenLab's innovation and validates the company's investment in research and development and intellectual property protection.PR NewswireNew U.S. Patents Granted for RegenLabRegen Lab SA and RegenLab USA LLC received two new U.S. patents from the USPTO covering technologies for preparing Thrombin Serum, Platelet Rich Plasma (PRP), and Hyaluronic Acid (HA). This grant increases the company's total portfolio of granted U.S. patents on these technologies to ten, reinforcing its intellectual property position in the medical device sector.PR NewswireSe conceden nuevas patentes en Estados Unidos para RegenLabRegen Lab SA and RegenLab USA LLC announced that the United States Patent and Trademark Office (USPTO) issued two new US patents covering their platelet-rich plasma (PRP), bone marrow concentrate (BMC), and hyaluronic acid (HA) technologies — US Patent numbers 10.052.349 and 10.064.894. This brings the company's total US patent portfolio to six, joining existing patents US8.529.957, US9.833.478, US9.833.478, US8.945.537, and US9.517.255. The company stated the patents validate its innovation and support ongoing intellectual property enforcement actions.PR NewswireNew U.S. Patents Granted for RegenLabThe USPTO issued two new U.S. patents to Regen Lab SA and RegenLab USA LLC covering their Platelet Rich Plasma, Bone Marrow Concentrate, and Hyaluronic Acid technologies. The new patents (U.S. Patent Nos. 10,052,349 and 10,064,894) bring the company's total U.S. granted patents to six, expanding RegenLab's intellectual property portfolio. The company stated the patents represent USPTO recognition of its innovation and that it will continue enforcing its intellectual property rights.PR NewswireNouveaux brevets américains accordés à RegenLabRegen Lab SA and its US subsidiary RegenLab USA LLC have been granted two new US patents by the USPTO, covering systems and methods for platelet-rich plasma (PRP) and bone marrow concentrate preparation, as well as PRP combined with hyaluronic acid. The new patents (US10052349 and US10064894) bring the company's total US patent portfolio for these technologies to six. The company stated that this USPTO recognition validates its innovation and technology, and strengthens its position to pursue intellectual property enforcement actions.